March 21, 2016
Consumer Groups Call on NIH to Lower Cancer Drug’s Price
Today the Alliance for Retired Americans joined the Center for the Study of Responsive Law, Universities Allied for Essential Medicines, American Medical Students Association, National Physicians Alliance, RxRights, Essential Information, Public Citizen, The Other 98%, U.S. PIRG and Community Catalyst in calling on Dr. Francis Collins, Director of the National Institutes of Health, to take action to reduce the price of Xtandi, an exorbitantly priced cancer drug.
“It is outrageous that Xtandi, a cancer drug created as a result of American taxpayer-funded research, is being sold in the United States for $350 per day. This is far more than Astellas Pharma, the Japanese manufacturer, is charging in other developed countries,” said Richard Fiesta, executive director of the Alliance for Retired Americans. “We urge Director Collins use his authority to make this cancer-fighting drug available to the public by forcing the company to charge a reasonable rate.”